How to buy Bellerophon Therapeutics stock (BLPH)

Bellerophon Therapeutics is a biotechnology business based in the US. Bellerophon Therapeutics shares (BLPH) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.01 – a decrease of 1.64% over the previous week. Bellerophon Therapeutics employs 18 staff and has a trailing 12-month revenue of around $5.6 million.

Our top picks for where to buy Bellerophon Therapeutics stock

Buy Bellerophon Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bellerophon Therapeutics stock price (PINK: BLPH)

Use our graph to track the performance of BLPH stocks over time.

Bellerophon Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.01
52-week range	$0.01 - $0.08
50-day moving average more info button	$0.04
200-day moving average more info button	$0.05
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.89

Bellerophon Therapeutics price performance over time

Historical closes compared with the close of $0.0161 from 2024-12-17

1 week (2024-12-14)	N/A
1 month (2024-11-25)	-70.73%
3 months (2024-09-21)	N/A
6 months (2024-06-21)	N/A

1 year (2023-12-21)	N/A
2 years (2022-12-21)	N/A
3 years (2021-12-21)	N/A
5 years (2019-12-21)	N/A

Bellerophon Therapeutics financials

Revenue TTM	$5.6 million
Gross profit TTM	$0
Return on assets TTM	-78.47%
Return on equity TTM	-165.96%
Profit margin	-164.06%
Book value	$0.30
Market Capitalization more info button	$146,792

TTM: trailing 12 months

Bellerophon Therapeutics share dividends

We're not expecting Bellerophon Therapeutics to pay a dividend over the next 12 months.

Have Bellerophon Therapeutics's shares ever split?

Bellerophon Therapeutics's shares were split on a 1:15 basis on 9 February 2020 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellerophon Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Bellerophon Therapeutics shares which in turn could have impacted Bellerophon Therapeutics's share price.

Bellerophon Therapeutics share price volatility

Over the last 12 months, Bellerophon Therapeutics's shares have ranged in value from as little as $0.01 up to $0.0785. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Bellerophon Therapeutics's is 0.704. This would suggest that Bellerophon Therapeutics's shares are less volatile than average (for this exchange).

Bellerophon Therapeutics overview

Bellerophon Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc.

Frequently asked questions

null
What percentage of Bellerophon Therapeutics is owned by insiders or institutions?
Currently 15.027% of Bellerophon Therapeutics shares are held by insiders and 8.394% by institutions. How many people work for Bellerophon Therapeutics?
Latest data suggests 18 work at Bellerophon Therapeutics. When does the fiscal year end for Bellerophon Therapeutics?
Bellerophon Therapeutics's fiscal year ends in December. Where is Bellerophon Therapeutics based?
Bellerophon Therapeutics's address is: 20 Independence Boulevard, Warren, NJ, United States, 07059 What is Bellerophon Therapeutics's ISIN number?
Bellerophon Therapeutics's international securities identification number is: US0787713009 What is Bellerophon Therapeutics's CUSIP number?
Bellerophon Therapeutics's Committee on Uniform Securities Identification Procedures number is: 078771300